Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE.

Int J Gynecol Pathol. 2019 May;38(3):230-240. doi: 10.1097/PGP.0000000000000513.

PMID:
29750700
2.

External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.

Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS.

J Gynecol Oncol. 2017 Nov;28(6):e73. doi: 10.3802/jgo.2017.28.e73. Epub 2017 Jul 24.

3.

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N.

J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29.

PMID:
26124480
4.

The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.

Singh P, Kaushal V, Rai B, Rajwanshi A, Gupta N, Dey P, Garg R, Rohilla M, Suri V, Ghoshal S, Srinivasan R.

Histopathology. 2018 Mar;72(4):619-625. doi: 10.1111/his.13399. Epub 2017 Dec 11.

PMID:
28914967
5.

Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy.

Michaan N, Chong WY, Han NY, Lim MC, Park SY.

Int J Gynecol Cancer. 2018 Nov;28(9):1676-1682. doi: 10.1097/IGC.0000000000001366.

PMID:
30256239
6.

Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.

Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay MHE, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA.

Int J Gynecol Cancer. 2017 May;27(4):708-713. doi: 10.1097/IGC.0000000000000945.

PMID:
28441251
7.

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CRS Collaborative Network (Supplementary 1), Singh N.

Gynecol Oncol. 2019 Aug;154(2):441-448. doi: 10.1016/j.ygyno.2019.04.679. Epub 2019 May 19. Review.

8.

The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma.

Said I, Böhm S, Beasley J, Ellery P, Faruqi AZ, Ganesan R, Hirschowitz L, Jeetle S, Leen SL, McCluggage WG, McDermott J, Merard R, Millner TO, Trevisan G, Vella J, Gilks CB, Singh N.

Int J Gynecol Pathol. 2017 Mar;36(2):172-179. doi: 10.1097/PGP.0000000000000307.

PMID:
27362902
9.

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.

Chung YS, Lee JY, Kim HS, Nam EJ, Kim SW, Kim YT.

Yonsei Med J. 2018 Oct;59(8):930-936. doi: 10.3349/ymj.2018.59.8.930.

10.

Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.

Okoye E, Euscher ED, Malpica A.

Am J Surg Pathol. 2016 May;40(5):627-35. doi: 10.1097/PAS.0000000000000615.

PMID:
26900814
11.

Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.

Rajkumar S, Polson A, Nath R, Lane G, Sayasneh A, Jakes A, Begum S, Mehra G.

Gynecol Oncol. 2018 Nov;151(2):264-268. doi: 10.1016/j.ygyno.2018.08.042. Epub 2018 Sep 6.

PMID:
30197060
12.

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.

Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R, Gilks B, Singh N.

Int J Gynecol Cancer. 2019 Jan 25. pii: ijgc-2018-000092. doi: 10.1136/ijgc-2018-000092. [Epub ahead of print]

PMID:
30683759
13.

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease.

Santoro A, Angelico G, Piermattei A, Inzani F, Valente M, Arciuolo D, Spadola S, Mulè A, Zorzato P, Fagotti A, Scambia G, Zannoni GF.

Front Oncol. 2019 Aug 19;9:778. doi: 10.3389/fonc.2019.00778. eCollection 2019.

14.

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).

Chung YS, Park SY, Lee JY, Park JY, Lee JW, Kim HS, Suh DS, Kim YH, Lee JM, Kim M, Choi MC, Shim SH, Lee KH, Song T, Hong JH, Lee WM, Lee B, Lee IH.

BMC Cancer. 2019 Apr 11;19(1):341. doi: 10.1186/s12885-019-5514-7.

15.

Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.

Zhang J, Liu N, Zhang A, Bao X.

J Obstet Gynaecol Res. 2018 Sep;44(9):1808-1816. doi: 10.1111/jog.13710. Epub 2018 Jul 18.

PMID:
30019801
16.

Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.

Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay ME, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA.

Int J Gynecol Cancer. 2017 May;27(4):708-713. doi: 10.1097/IGC.0000000000000945.

PMID:
30814178
17.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators.

Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413383
18.

Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.

Massari R, Barone M, Basilico R, Carella C, Colasante A, De Tursi M, Filippone A, Guetti L, Mani A.

Minerva Chir. 2014 Feb;69(1):17-26.

PMID:
24675243
19.

Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.

Petrillo M, Zannoni GF, Tortorella L, Pedone Anchora L, Salutari V, Ercoli A, Margariti PA, Scambia G, Fagotti A.

Am J Obstet Gynecol. 2014 Dec;211(6):632.e1-8. doi: 10.1016/j.ajog.2014.06.034. Epub 2014 Jun 19.

PMID:
24954656
20.

Preoperative omental metastasis-related maximum standardized fluorine-18-fluorodeoxyglucose uptake value can predict chemosensitivity and recurrence in advanced high-grade serous ovarian cancer patients.

Sun Y, Liu S, Feng Z, Cheng J, Lu L, Wang M, Yuan H, Xu J, Zhang Y.

Nucl Med Commun. 2018 Aug;39(8):761-767. doi: 10.1097/MNM.0000000000000865.

PMID:
30001265

Supplemental Content

Support Center